Cargando…
CRISPR/Cas9 Approach to Generate an Auxotrophic BCG Strain for Unmarked Expression of LTAK63 Adjuvant: A Tuberculosis Vaccine Candidate
Tuberculosis is one of the deadliest infectious diseases and a huge healthcare burden in many countries. New vaccines, including recombinant BCG-based candidates, are currently under evaluation in clinical trials. Our group previously showed that a recombinant BCG expressing LTAK63 (rBCG-LTAK63), a...
Autores principales: | Moraes, Luana, Trentini, Monalisa Martins, Fousteris, Dimitrios, Eto, Silas Fernandes, Chudzinski-Tavassi, Ana Marisa, Leite, Luciana Cezar de Cerqueira, Kanno, Alex Issamu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9005855/ https://www.ncbi.nlm.nih.gov/pubmed/35432328 http://dx.doi.org/10.3389/fimmu.2022.867195 |
Ejemplares similares
-
Recombinant BCG expressing the LTAK63 adjuvant improves a short-term chemotherapy schedule in the control of tuberculosis in mice
por: Trentini, Monalisa Martins, et al.
Publicado: (2022) -
Recombinant BCG expressing the LTAK63 adjuvant increased memory T cells and induced long-lasting protection against Mycobacterium tuberculosis challenge in mice
por: Marques-Neto, Lázaro Moreira, et al.
Publicado: (2023) -
Recombinant BCG expressing the LTAK63 adjuvant induces increased early and long-term immune responses against Mycobacteria
por: Carvalho Dos Santos, Carina, et al.
Publicado: (2019) -
Recombinant BCG-LTAK63 Vaccine Candidate for Tuberculosis Induces an Inflammatory Profile in Human Macrophages
por: dos Santos, Carina C., et al.
Publicado: (2022) -
Recombinant BCG Expressing LTAK63 Adjuvant induces Superior Protection against Mycobacterium tuberculosis
por: Nascimento, Ivan P., et al.
Publicado: (2017)